Safety, Tolerability, Effectiveness, and Pharmacokinetic Data in Opioid-experienced Children

Summary

The purpose of this study was to assess the safety and pharmacokinetics (single- and multiple-dose) of oxymorphone ER for the relief of moderate to severe pain in pediatric participants ages 7 - ≤17 years old requiring a continuous, around-the-clock (ATC) opioid treatment for an extended period.

Timeline

Start

2013-03-11

Primary completion

2017-04-04

Completion

2021-01

Drugs

Indications